⌘K

Login Start Free

Home/Filings/4/0001818382-22-000174

4//SEC Filing

Cao Yang 4

Accession 0001818382-22-000174

CIK 0001818382other

View on SEC.gov Company Profile

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 4:09 PM ET

Size

5.4 KB

Accession

0001818382-22-000174

Insider Transaction Report

Form 4

Period: 2022-09-19

Humacyte, Inc.HUMA

Chief Regulatory Officer

Transactions

Award
Stock Options (right to buy)
2022-09-19+145,000→ 145,000 total
Exercise: $3.73Exp: 2032-09-19→ Common Stock (145,000 underlying)

Footnotes (1)

[F1]The first 25% of the option becomes exercisable on September 19, 2023, after which 1/48 of the option will become exercisable on the 19th of each month through September 19, 2026.

Documents

1 file

4
wf-form4_166370457260068.xmlPrimary
FORM 4

Issuer

Humacyte, Inc.

CIK 0001818382

Entity typeother

Related Parties

1

filerCIK 0001946538

Filing Metadata

Form type: 4
Filed: Sep 19, 8:00 PM ET
Accepted: Sep 20, 4:09 PM ET
Size: 5.4 KB

View on SEC.gov